These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38644155)

  • 1. Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.
    Cerrato C; Crocerossa F; Marchioni M; Giannarini G; Gupta S; Albiges L; Brouwer O; Albersen M; Fankhauser C; Grimm MO; Gandaglia G; Roupret M; Mir MC;
    Eur Urol Oncol; 2024 Oct; 7(5):1005-1014. PubMed ID: 38644155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
    World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021.
    Tapia JC; Bosma F; Gavira J; Sanchez S; Molina MA; Sanz-Beltran J; Martin-Lorente C; Anguera G; Maroto P
    Clin Genitourin Cancer; 2024 Jun; 22(3):102047. PubMed ID: 38430859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis.
    Monteiro FSM; Soares A; Mollica V; Leite CA; Carneiro APCD; Rizzo A; Bourlon MT; Sasse AD; Santoni M; Gupta S; Massari F
    Crit Rev Oncol Hematol; 2024 Apr; 196():104321. PubMed ID: 38460929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Mori K; Yanagisawa T; Fukuokaya W; Iwatani K; Matsukawa A; Katayama S; Pradere B; Laukhtina E; Rajwa P; Moschini M; Albisinni S; Krajewski W; Cimadamore A; Del Giudice F; Teoh J; Urabe F; Kimura S; Murakami M; Tsuzuki S; Miki J; Miki K; Shariat SF; Kimura T;
    Int J Urol; 2024 Jan; 31(1):25-31. PubMed ID: 37840031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Zhang Y; Chen J; Liu H; Dai J; Zhao J; Zhu S; Zhang X; Liang J; Hu X; Zhao J; Liu Z; Shen P; Sun G; Zeng H
    Cancer Treat Rev; 2024 Sep; 129():102787. PubMed ID: 38905806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era in the treatment of urothelial carcinoma.
    Faltas B
    Urol Oncol; 2023 Oct; 41(10):395-397. PubMed ID: 37833099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Kardoust Parizi M; Matsukawa A; Bekku K; Klemm J; Alimohammadi A; Laukhtina E; Karakiewicz P; Chiujdea S; Abufaraj M; Krauter J; Shariat SF
    Eur Urol Oncol; 2024 Aug; 7(4):663-676. PubMed ID: 37980251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
    Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
    Int J Clin Oncol; 2024 Aug; 29(8):1096-1104. PubMed ID: 38850448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis.
    Hassler MR; Abufaraj M; Kimura S; Stangl-Kremser J; Gust K; Glybochko PV; Schmidinger M; Karakiewicz PI; Shariat SF
    Clin Genitourin Cancer; 2020 Apr; 18(2):88-94.e2. PubMed ID: 31668768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Tural D; Arslan C; Selcukbiricik F; Olmez OF; Erman M; Ürün Y; Erdem D; Kilickap S
    Clin Genitourin Cancer; 2024 Oct; 22(5):102163. PubMed ID: 39126823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
    Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
    Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
    Hwang I; Park I; Yoon SK; Lee JL
    Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
    Yanagisawa T; Kawada T; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Chlosta M; Quhal F; Pradere B; Karakiewicz PI; Mori K; Kimura T; Shariat SF; Schmidinger M
    BJU Int; 2024 Sep; 134(3):323-336. PubMed ID: 38659099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy Plus Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Advanced Urothelial Cancer: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Mamede I; Escalante-Romero L; Celso DSG; Reis PCA; Dacoregio MI; Alves AC; Stecca C
    Clin Genitourin Cancer; 2024 Oct; 22(5):102154. PubMed ID: 39094286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.